Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C21H24N2O2.ClH |
Molecular Weight | 372.888 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.[H][C@]12[N@]3C[C@H](C[C@]1(C(=O)OC)C4=C(CC3)C5=CC=CC=C5N4)C=C2CC
InChI
InChIKey=AVBOKMGDTOZFMW-GYMDHWDQSA-N
InChI=1S/C21H24N2O2.ClH/c1-3-14-10-13-11-21(20(24)25-2)18-16(8-9-23(12-13)19(14)21)15-6-4-5-7-17(15)22-18;/h4-7,10,13,19,22H,3,8-9,11-12H2,1-2H3;1H/t13-,19+,21-;/m0./s1
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/23532933Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/13641069 | https://www.ncbi.nlm.nih.gov/pubmed/23532933
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23532933
Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/13641069 | https://www.ncbi.nlm.nih.gov/pubmed/23532933
Catharanthine is a terpene indole alkaloid produced by the medicinal plant Catharanthus roseus. Catharanthine is derived from strictosidine, but the exact mechanism by which this happens is currently unknown. Catharanthine is one of the two precursors that form vinblastine, the other being vindoline.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL3108632 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25052206 |
0.9 µM [IC50] | ||
Target ID: CHEMBL6007 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25052206 |
9000.0 nM [EC50] | ||
Target ID: CHEMBL4794 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25052206 |
20.0 µM [EC50] | ||
Target ID: CHEMBL2095177 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23532933 |
220.0 µM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23532933
Intravenous administration of catharanthine (0.5–20 mg/kg) to anesthetized rats induced rapid, dose-dependent decreases in blood pressure, heart rate, left ventricular blood pressure, cardiac contractility, and the slope of the end-systolic pressure-volume relationship curve.
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23532933
Catharanthine evoked concentrationdependent decreases in endothelium-independent tonic responses of aortic rings to phenylephrine (PE) and KCl (IC50 = 5 28 uM for PE and IC50 =5 34 mM for KCl) and of thirdorder branches of the small mesenteric artery (IC50 = 3 mM for PE and IC50 = 6 mM for KCl)
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
5458189
Created by
admin on Sat Dec 16 09:51:49 GMT 2023 , Edited by admin on Sat Dec 16 09:51:49 GMT 2023
|
PRIMARY | |||
|
V75368O53K
Created by
admin on Sat Dec 16 09:51:49 GMT 2023 , Edited by admin on Sat Dec 16 09:51:49 GMT 2023
|
PRIMARY | |||
|
2645-61-6
Created by
admin on Sat Dec 16 09:51:49 GMT 2023 , Edited by admin on Sat Dec 16 09:51:49 GMT 2023
|
PRIMARY | |||
|
DTXSID90949338
Created by
admin on Sat Dec 16 09:51:49 GMT 2023 , Edited by admin on Sat Dec 16 09:51:49 GMT 2023
|
PRIMARY | |||
|
220-159-1
Created by
admin on Sat Dec 16 09:51:49 GMT 2023 , Edited by admin on Sat Dec 16 09:51:49 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD